RNS Number : 5419J
ReGen Therapeutics PLC
04 December 2008
4 December 2008
ReGen Therapeutics Plc
Full Results of Study Showing how ReGen's Colostrinin* achieves its
Clinical effect Published in Peer-reviewed Journal
ReGen Therapeutics Plc ("ReGen" or the "Company"), is pleased to announce that the full results of this genomic microarray study, which
was first reported as part of ReGen's Interim Results statement issued on the 23rd September 2008, has now been published on-line ahead of
availability in print by the peer-reviewed journal International Immunopharmacology.
We emphasise two key points of the article. Firstly, Colostrinin* can favourably modulate the expression of several molecules involved
in the pathology of Alzheimer's disease - upregulation of bleomycin hydrolase, downregulation of APP and effect on Tau phosphorylation.
Given that Alzheimer's is a complex disease, the multi-faceted action shown by Colostrinin* is significant. Secondly, Colostrinin* also
modulates other molecules involved in biological pathways associated with other conditions such as obesity and allergy.
ReGen's Chairman and Chief Executive, Percy Lomax said:
"For a long time ReGen has had compelling experimental and clinical data that suggest Colostrinin* achieves its clinical effect and
support our belief that it is one of the first compounds with the potential to impact both Tau tangles and beta amyloid plaques, the two key
pathologies of Alzheimer's disease. Publication of the research will be a useful tool in the further commercialisation of the product".
The abstract of this study is reproduced below. The text of the full article (charged) is now available at:
www.ncbi.nlm.nih.gov/pubmed/ by searching on the name of the first author.
For further information:
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Tel No 020 7628 3396
Nick Bealer/David Scott
Tel No 020 7448 9820
Adrian Duffield/Jon Davies
College Hill Associates
Tel No 020 7457 2020
Effects of Colostrinin on gene expression-transcriptomal network analysis.
Szaniszlo P, German P, Hajas G, Saenz DN, Woodberry MW, Kruzel ML, Boldogh I.
Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States.
Colostrinin (CLN) is a uniform mixture of low-molecular weight proline-rich polypeptides isolated from the mother's first milk,
colostrum. Exposure of cells to CLN decreases intracellular levels of reactive oxygen species by regulating glutathione metabolism and
modulating activities of antioxidant enzymes and mitochondrial function. It also inhibits beta amyloid-induced apoptosis and induces neurite
outgrowth of pheochromocytoma cells. Administration of CLN to Alzheimer's disease patients has resulted in a stabilizing effect on cognitive
function. We analyzed CLN-induced gene expression changes using high-density oligonucleotide arrays and transcriptomal network analysis. We
found that CLN elicited highly complex and multiphasic changes in the gene expression profile of treated cells. CLN treatment affected a
total of 58 molecular networks, 27 of which contained at least 10 differentially expressed genes. Here we present CLN-modulated gene
networks as potential underlying molecular mechanisms leading to the reported effects of CLN on cellular oxidative state, chemokine and cytokine production, and cell differentiation, as well as on
pathological processes like allergy, asthma, Alzheimer's, and other neurological diseases. Based on our results, we also predict possible
modulatory effects of CLN on adipocytokine gene networks that play a crucial role in the pathobiology of diabetes, cardiovascular disorders,
obesity, and inflammation. Taken together, CLN-altered gene expression networks presented here provide the molecular basis for previously
described biological phenomena and predict potential fields of application for CLN in the prevention and treatment of diseases.
This information is provided by RNS
The company news service from the London Stock Exchange